BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21674853)

  • 1. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study.
    Spiliotis J; Vaxevanidou A; Sergouniotis F; Lambropoulou E; Datsis A; Christopoulou A
    J BUON; 2011; 16(1):74-9. PubMed ID: 21674853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome.
    Fagotti A; Costantini B; Vizzielli G; Perelli F; Ercoli A; Gallotta V; Scambia G; Fanfani F
    Gynecol Oncol; 2011 Aug; 122(2):221-5. PubMed ID: 21543112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
    Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
    Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer].
    Ferron G; Martinez A; Mery E; Querleu D; Thomas F; Chatelut E; Gladieff L
    Bull Cancer; 2009 Dec; 96(12):1243-52. PubMed ID: 19948452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
    Argenta PA; Sueblinvong T; Geller MA; Jonson AL; Downs LS; Carson LF; Ivy JJ; Judson PL
    Gynecol Oncol; 2013 Apr; 129(1):81-5. PubMed ID: 23352917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.
    Carrabin N; Mithieux F; Meeus P; Trédan O; Guastalla JP; Bachelot T; Labidi SI; Treilleux I; Rivoire M; Ray-Coquard I
    Bull Cancer; 2010 Apr; 97(4):E23-32. PubMed ID: 20202920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
    van der Vange N; van Goethem AR; Zoetmulder FA; Kaag MM; van de Vaart PJ; ten Bokkel Huinink WW; Beijnen JH
    Eur J Surg Oncol; 2000 Nov; 26(7):663-8. PubMed ID: 11078613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women.
    Delotte J; Arias T; Guerin O; Boulahssass R; Bereder I; Bongain A; Benchimol D; Bereder JM
    Acta Obstet Gynecol Scand; 2015 Apr; 94(4):435-9. PubMed ID: 25675854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.
    Pavlov MJ; Kovacevic PA; Ceranic MS; Stamenkovic AB; Ivanovic AM; Kecmanovic DM
    Eur J Surg Oncol; 2009 Nov; 35(11):1186-91. PubMed ID: 19356887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive surgery (cs) and hyperthermic intraperitoneal chemotherapy (hipec) in treatment of peritoneal surface malignances: report of a phase II clinical study.
    Asero S; Caruso M; Vallone N; Luciani AG; Lombardo V; Terranova G; Ettore G; Giannone G
    In Vivo; 2009; 23(4):645-7. PubMed ID: 19567402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
    Safra T; Grisaru D; Inbar M; Abu-Abeid S; Dayan D; Matceyevsky D; Weizman A; Klausner JM
    J Surg Oncol; 2014 Nov; 110(6):661-5. PubMed ID: 24962381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is hyperthermic intraoperative peritoneal chemotherapy and systemic chemotherapy as effective as standard intraperitoneal chemotherapy: time for a prospective trial?
    Edwards RP
    Gynecol Oncol; 2011 Aug; 122(2):207-8. PubMed ID: 21763889
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
    Helm CW; Randall-Whitis L; Martin RS; Metzinger DS; Gordinier ME; Parker LP; Edwards RP
    Gynecol Oncol; 2007 Apr; 105(1):90-6. PubMed ID: 17173957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
    Roviello F; Pinto E; Corso G; Pedrazzani C; Caruso S; Filippeschi M; Petrioli R; Marsili S; Mazzei MA; Marrelli D
    J Surg Oncol; 2010 Nov; 102(6):663-70. PubMed ID: 20721959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
    Fagotti A; Paris I; Grimolizzi F; Fanfani F; Vizzielli G; Naldini A; Scambia G
    Gynecol Oncol; 2009 Jun; 113(3):335-40. PubMed ID: 19345401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
    Halkia E; Spiliotis J
    J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
    Yang XJ; Li Y; al-shammaa Hassan AH; Yang GL; Liu SY; Lu YL; Zhang JW; Yonemura Y
    Ann Surg Oncol; 2009 Feb; 16(2):345-51. PubMed ID: 19018599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience.
    Carmignani CP; Sugarbaker PH
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):477-87. PubMed ID: 15161446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma.
    Lentz SS; Miller BE; Kucera GL; Levine EA
    Gynecol Oncol; 2007 Jul; 106(1):207-10. PubMed ID: 17498782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.